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ABSTRACT 
A number of potential anticancer compounds exhibit solubility and 
stability problems (1,2). This study examined the solubility of AZQ 
(NSC-1 82986) in water and various solvent systems, with the 
following aims: 
1. To expand knowledge of the physical and chemical properties 
of AZ Q, and 
2. To serve as a valuable preformulation compilation of data to 
identify solvents which enhance the solubility of AZQ, and 
have poten tial fo r human us e . 
In this study, a rapid, simple, selective, and sensitive 
stability-indicating high-performance liquid chromatographic (HPLC) 
assay was developed for the simultaneous identification and quan-
tification of AZQ. 
Of all the solvents tested, the solubility of AZQ in dimethyl-
acetamide (OMA) was the best, followed by ethanol 95% and other 
lipid solvents. Phosphate buffer, at pH = 6.5, was a good solvent 
as compared to plain distilled water in that degradation was 
reduced. The effects of temperature were also studied. It was very 
clear from the results obtained that raising the incubation tern-
perature from 25°C to 40°C led to the decline in the solubility of 
AZQ in phosphate buffer, water and peanut oil as solvents. Optimum 
temperature for maximum solubility was found to be 35°C. 
1 Developmental Therapeutic Program, National Cancer Institute, 
National Institutes of Health, Bethesda, Md. 
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1. INTRODUCTION 
1.1 Chemotherapeutic agents for the treatment of Cancer 
A basic goal of cancer chemotherapy is to discover drugs that 
will control the growth of cancer cells or destroy them without 
serious damage to the normal tissues of the host. Although the 
search for drugs with a selective action against cancer has occupied 
the scientific and medical community throughout the world for a long 
time, this objective has yet to be substantially achi~ved. 
The model of the selective therapeutic activity of the sulfon-
amides and antibiotics on bacterial infections in man continues to 
spur investigators in cancer chemotherapy. Researchers envision 
that substances possibly exist or ultimately will be synthesized 
which have a high therapeutic index against cancer (3). 
Screening programs, principally based on the use of laboratory 
ani mals inoculated ~ith transplantable tumors or leukemias are 
presently employed to test a vast array of chemicals, antibiotics, 
and plant tissue extracts for anti-cancer activity (3). 
Screening programs have discovered drugs that exhibit therapeutic 
activity in man, but only in rare patients do they cause a sustained 
response. In cancer, unlike in bacterial infections, there is no 
well-defined immunological or cellular defense against residual 
cancer cells. 
In view of these facts, the proper use of the available anti-
cancer drugs involves appreciation of the disease in the individual 
cancer patient and his reaction to his cancer, the host metabolism 
( 2 
of the dr ug and the effects of the drugs on host t i ssues and fun c-
tions , as we ll as t heir direc t eff ec ts on the neop l ast i c process (3 ) 
(Figure 1) . 
FIGUR E 1: INTERRE LATION OF HOST, CANCER AND ANTI-CANCER DR UG 
DRUG 
Mechanism of action 
Subcellular 
Cellular 
Whole animal 
CANCER 
Site of origin 
Structure 
Biochemical properties 
Functions 
Antigenicity? 
Toxicity 
Effect on normal processes 
Metabolism of drug 
HOST 
Cell proliferation 
Tissue reactions 
Organ functions 
Immune status 
Interrelations between drug, host, and cancer in vivo in the analy-
sis of the mechanism of action of an anit-cancer drug. The separate 
entities are the properties of the drug, the status of the host, and 
the specific properties of the cancer . These factors must be eval-
uated separately and in their complex interrelationship interpreting 
the therapeutic and toxicologic actions of a drug in specific clin i -
cal situations (4). Cole, W 1970. 
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FIGURE 2: SITE OF ACTION OF CHEMOTHERAPEUTIC AGENTS 
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( 5) Co le, W. 1970. 
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1.2 Properties of AZQ and related compounds: 
The National Cancer Institutes (NCI) is a branch of the National 
Institute of Health in Bethesda, Maryland. The NCI has been charged 
with the responsibility of developing and manufacturing pharma-
ceutical dosage forms of potential anti-tumor agents for subsequent 
evaluation in preclinical toxicology studies and in clinical studies. 
The NCI's drug development activity has utilized the intravenous 
route as the primary mode of administration for most new anti-tumor 
compounds because these compounds have simple formulations and this 
route provides maximal bioavailability. 
While some drugs exhibit adequate aqueous solubility and stabil-
ity for intravenous delivery by formation of either a water-soluble 
salt or by the addition of water-miscible solvents, a significant 
number of potential anti-cancer agents cannot be formulated in this 
manner because of solubility and/or stability problems. 
The aziridinylbenzoquinones constitute a class of quinones that 
exhibit significant anti-tumor activity against i.p. implanted 
lymphoid leukemia (6,7). (See Figure 2). AZQ or Oiaziquone was 
determined to be the superior analog of the 31 aziridinylben-
zoquinones tested (8). AZQ or Diaziquone was rationally synthesized 
to produce a compound possessing the three properties necessary to 
penetrate the Central Nervous System (CNS) (6): 
i. Good lipid solubility; 
ii. Low ionization, and 
iii. Adequate aqueous solubility (9,10). 
( 
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The structure of AZQ suggests that it has alkylating activity. 
However, when a modified chemical test was used (11), no alkylating 
activity was detected under physiological conditions (i.e. incu-
bating at 37°C). When the incubation temperature was raised to 
100°C, alkylating activity equal to three-fourths the alkylating 
activity of nitrogen mustard was shown. 
Although the exact mechanism of action of AZQ is unknown, mem-
bers of this class of compounds are known to cross-link DNA (12). 
AZQ (NSC-182986), (13, 14, 15), an aziridinylbenzoquinone, which 
was developed by the NCI, has been sho11n to be active against brain 
tumors, but its solubility in water and other aqueous systems is 
quite poor. while adequate levels in the blood can be achieved with 
dimethylacetamide (OMA), (16,17), an aqueous system is preferred or 
desirable for safety. 
( 
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FIGURE 3: STRUCTURE OF AZQ AND ITS RELATED COMPOUNDS 
0 
CH3CH20-C-NH 
~: 
II o 
0 
I: R 1 = R 1 = -N(] 
II: R 1 - -N<], ·R 2 = NH.CH 2 CH 2 0H 
III: R, = R 2 z NHCH 2CH 20H 
= AZQ (NSC-182986) 2,5 diaziridinyl - 3,6 - bis 
(carboethoxyamino)-1,4-benzoquinone 
II = 2-Aziridinyl-5- (2'-hydroxyethylamino)-3,6-bis (carbo-
ethoxyamino)-1,4-benzoquinone 
III = 2,5-di (2'-hydroxyethylamino)-3,6-bis (carboethoxyamino)-
1,4-benzoquinone. 
II and III are hydrolytic degradation products of AZQ (I) which were 
isolated by semi-preparative HPLC from I. (ref. 18). 
( 
1.3 Utility of Preformulation and its relevance to therapy, with 
special reference to solubility: 
"Preformulation involves the application of biopharmaceutical 
principles to the physico-chemical parameters of a drug with the 
goal of designing an optimum drug delivery system" (19). 
7 
The cost to develop new drugs or dosage forms is very high and 
preforniulation studies can help to minimize this expense if they are 
initiated at the time of discovery of new compounds with promising 
pharmacological activity. It is very useful to make this study 
prior to either formulation or clinical formulation, to minimize the 
cost and effort of drug development. The parameters to be studied 
should include the following: chemical stability, aqueous solubi-
lity, pKa and dissolution rate. 
Priority must be given to the effect of various diluents, pH and 
temperature on the chemical stability of the drug. These investiga-
tions should precede any attempt to design new dosage forms. In 
addition to the above parameters, preliminary, in vivo, animal stu-
dies of drug absorption, metabolism, protein-binding, distribution, 
and elimination are also part of preformulation. 
The major goal of preformulation studies is to gather data which 
will permit a rational development of safe and useful dose forms. 
The importance of chemical stability of the drug cannot be over-
emphasized because the administration of degraded products might 
result in either sub-therapeutic blood-levels of the drug, or 
possibly, toxic effects. So, in order to formulate stable dosage 
( 
forms, the effects of pH, humidity, temperature and other factors 
must therefore be known (19). 
8 
Solubility is a very important aspect of preformulation. Orally 
administered drugs must dissolve in the fluids of the gastroin-
testinal tract (GIT) before the drug can be absorbed. These drugs 
must have sufficient aqueous solubility to achieve the desired dose 
level. It has generally been found by Kaplan that potential 
bioavailability or absorption problems are often present when the 
aqueous solubility of a drug is less than 1 gram per 100~1., in 
a pH range of 1 to 8 (20). In preformulation studies, solubility 
studies are performed by the addition of excess of drug to buffer 
solutions having a pH in the range of 1 to 8. Vials containing the 
drug and buffer and/or solvent, are often agitated at 37°C, with 
samples being removed at timed intervals, filtered, and assayed for 
drug content (21). The experiment is completed when the measured 
drug content or concentration is constant. 
Results from this type of experiments yield data on solubility 
of the drug, that is, saturation solubility. Care should be taken if 
the study is done at elevated temperatures that sampling be done at 
the same temperature to avoid supersaturation. Also enough time 
should be allowed for equilibration, and it should be remembered 
that if not detected, degradation may give false readings. So, it 
is essential that a stability-indicating assay be a requisite part 
of this study. 
( 
( 
9 
Preformulation data is a useful guideline in formulation in that 
it points out which solvents are good for the drug. But the problem 
of dilution still exists. How much solvent or, what level of 
solvent is acceptable at the time of use? 
Buffer solutions may be used to increase the solubility of 
va rious drugs, the enhanced solubility due to salt formation. The 
undissolved phase in equilibrium with the saturated solution, 
comprises unreacted acid. By applying the correct pH in a for-
mulation of a dosage form, maximum solubility and stability may be 
achieved, but this pH must be acceptable for the particular route of 
admini stration. Many buffer systems are possible, but toxic 
effects, $UCh as generation of harmful or inactive degradation pro-
ducts, when administered orally and parenterally, severely limit the 
number of buffer systems that may be used in pharmaceuticals. 
The physical and chemical stability of a dosage form must be 
known to ensure that the patient receives the prescribed dose of a 
drug and not a therapeutically inactive degradation product. Chemical 
stability is important since many medicinal compounds are esters, 
amides, or lactams. Hydrolysis is the most frequently encountered 
type of degradation in pharmaceuticals. Hydrogen and hydroxyl ions 
are the most common catalysts of hydrolytic degradation in solutions 
(22). The correct use of buffer solutions will help prevent this 
problem. 
Photolysis is another source of chemical instability. Molecules 
absorb the proper wavelength of light and acquire sufficient energy 
to undergo reactions. Photolytic degradation usually occurs upon 
( 
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exposure to light of wavelength less than 400 ~· Use of amber 
glass bottles or an opaque container will act as a barrier to this 
light. 
Autoxidation is the spontaneous reaction under ordinary con-
ditions of a drug with atmospheric or molecular oxygen. It is 
believed that most oxidation reactions involve a free radical an d 
chain reactions (23) • Traces of metallic ions originating in the 
drug, solvent, or container may initiate oxidation reactions. As a 
precaution, chelating agents such as ethylenediaminetetraacetic acid 
(EDTA), may be added to bind any metal present. 
• 
Physical and chemical stability are very important aspects of 
formulation. Injections must be able to withstand sterilization by 
means of chemical, mechanical and physical processes. Color changes 
are also a result of degradation. Solutions may undergo a change in 
consistency and odor as a result of degradation. Emulsions may break 
or sediment due to degradation. These factors must all be consid-
ered in the development of a new formulation drug product. 
In general, 11 substances dissolve faster if the system is warmed. 
If a substance absorbs heat in the dissolution process, its solubi-
lity is increased by an increase in temperature, 11 (24). It is known 
that this increase in solubility provides an increased concentration 
gradient, which leads to an increased dissolution rate. The 
increased temperature of the system, increases kinetic motion and 
diffusion of the solute through the diffusion layer into the bulk 
solution, which increases the dissolution rate (24). 
Arrhenius expressed this relationship between temperature and 
reaction rate as: 
k = A exp (-Ea/RT) 
where: Ea = molar activation energy 
R =Gas Constant (l.987 cal. mole-1 deg -1). 
k = reaction -rate constant 
T =absolute temperature (°Kelvin). 
11 
A= frequency factor; A embraces the number of collisions 
of t he molecules and the probability that the orien-
tation of the collidi ng molecules is such that a reac-
tion may occur (25). 
This equation has found general use in accelerated stability 
tests in order to predict the rate of decomposition at room tem-
perature. 
Care should be taken that no adverse interactions occur between 
the drug, the excipients and the container of the new formulation. 
Also no interaction should occur between the excipients themselves, 
as this might impair the integrity of the product. Incompatibilities 
within a formulation might lead to untoward physical and chemical 
changes in the formulation, with the result that the product of this 
kind might have limited or even undesirable therapeutic and/or toxic 
effects, e.g. precipitation of an injection product; breaking of an 
emulsion; hardening of tablets, etc. 
Solubility data is just one aspect of formulation because of the 
need for parenterally acceptable and compatible excipients. This 
( 
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solubility of the formulation is also a major issue to be investi-
gated. Other limitations include the degradation of the drug in 
solution and, in the case of a suspended solid (suspension), the 
rate of dissolution must be known. 
1.4 Problems associated with NCI drugs: 
Many compounds are synthesized with the intent of producing 
selective cytotoxic activity in a variety of cancers. Typically, 
the solubility in water or blood serum of these compounds is a major 
concern and their stability in solution, are quite limited. 
Examples of NCI drugs as well as their associated formulation 
problems, include (26): 
a) Taxol brevifolia, is currently formulated in castor oil/ethanol 
at concentrations of 6 mg/ml and is diluted to 0.6 mg/ml. before 
use. In spite of having excellent solubility in 75% PEG, the 
antitumor activity is reduced in this formulation. The cause 
of this reduction was not known but is not due to chemical degra-
dation. The NCI prefers a formulation in the CremophorR, in a 
deliverable concentration of 20-25 mg/ml. 
b) AZQ (NSC-182986), an aziridinyl benzoquinone which has shown 
activity in brain tumors. However, its solubility in water and 
other aqueous systems is quite poor. A system other than 
dimethylacetamide (OMA) as a solvent is desirable. The desirable 
concentration is 10-20 mg/ml. since intrathecal administration is 
being considered. (See Table I). 
c. Mitindomide (NSC-284356), a diimide active in several tumor model 
systems. The disodium salt is soluble at high pH ( >10.5 ), but 
13 
decomposes rapidly. Mitindomide is essentially insoluble in 
water and most common solvents. The NCI's solubility goal is 20 
mg/ml. 
d. Hexamethylmelamine (NSC-13875), has been used as an oral product 
in combination with other drugs, to treat ovarian cancers. The 
daily dose requirement is approximately 350 mg/m2 (approx. 700 mg 
per dose). This oral product causes gastrointestinal toxicity. 
An aqueous intravenous delivery system is desirable, which would 
provide a deliverable dose of approximately 700 mg per dose. 
The four products mentioned above illustrate some of the most 
important formulation problems presented by potentially useful anti-
tumor drugs. 
To overcome solubility problems, various techniques have been 
employed. A sampling of some of these methods is discussed below. 
Colloidal dispersions of micelles have been used in pharmacy to 
solubilize water insoluble materials. Oil-soluble vitamins are 
dispensed in aqueous multivitamin liquids as a result of solubiliza-
tion by nonionic surface-active agents. The solubilization of a 
substance may improve its chemical stability by protecting it in 
micelles. Solubilized Vitamin A is more stable to autoxidation than 
its oily solution.(29) 
( 
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TABLE I: RELATIVE SOLUBILITY OF AZQ IN DIFFERENT SOLVENTS 
SOLVENT SOLUBILITY (MG/ML) 
Water 0.72 
pH4 Aceta t e Buff er Less than 1 
pH9 Borate Buff er Less than 1 
10% Ethanol Less than 1 
95% Ethanol Less than 1 
Methanol Less than 1 
Chlo roform Between 5 and 7 
Dimethylacetamide (OMA) Between 20 and 25 
5% OMA 1.5 
Dimethylsulfoxide (DMSO) Between 25 and 30 
NOTE: Data provided by National Cancer Institute (NCI) (27,28) 
Approximate solubility found by visual observation after one hour's 
shaking on a LabquakeR Shaker. 
Aqueous solutions of AZQ decompose readily in 5% OMA, at room-temp 
18% lost in 8 hours. 
( 
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An oral suspension is an advantageous dosage form for administra-
tion to patients who cannot swallow tablets and capsules. 
Generally, a solid content of a suspension may range from 250 to 500 
mg per teaspoonful. The shelf-life of a suspension of a drug is 
often greater than that of its solution, because of the extremely 
small amount of drug which is dissolved and thus subjected to degra-
dation. Parenteral suspensions are injected subcutaneously and 
intramuscularly but not intravenously nor into the spinal canal 
(30 ) . This type of dosage form can provide a means of prolonged 
release of drug. 
• 
The purpose of emulsification is to administer a uniform blend 
of immi scible liquids in a single preparation. Oral emulsions are 
generally the oil-in-water type where the emulsifying agent surrounds 
the oil so that the oily feel and taste are minimized. Only a few 
parenteral emulsions have been used successfully in the administra-
tion of phytonadione (Vitamin K) and in the intravenous feeding of 
rats. Unwanted physiological effects, e.g. febrile reaction and 
hemol ysis, have limited the use of these intravenous emulsions (31). 
These systems are also subject to instability, primarily by 
coalescence. 
pH is an important aspect of the stability of drugs in solution. 
The pH-rate profile of AZQ was shown to have a degradation minimum 
between pH 6.0 and 6.5 (32). The route of administration determines 
the pH range to which the drug can be formulated, e.g. with small-
volume injections, a fairly large deviation from physiological pH 
( 
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is tolerated because the blood buffers can readily adjust and main-
tain the blood at normal pH. 
Since the National Cancer Institute (NCI) is only able to pro-
vide a limited amount of test drug (i-3 grams), there exists a need 
to develop a micro-scale technique to generate and evaluate the 
required data. A procedure as described below, can produce the sen-
sitivity required when working with very small quantities of a com-
pound: 
1. development of a micro-assay method using ultraviolet (UV) 
spectroscopy or High-Performance Liquid Chromatograph} (HPLC) method 
(stability indicating) to indicate that decomposition has not 
occured over a time period or that decomposition products do not 
interfere with identification of the compound; 
2. validation of this method using FDA guidelines; 
3. use of this method on the test drug to generate solubility data 
for comparison with literature values. This will enable the 
establishment of the miniaturization assay as valid in terms of 
accuracy and reproducibility. 
4. screening other selected solvents such as propylene glycol, etha-
nol, ~1ater, buffers, OMA and aqueous mixtures of these solvents to 
maximize solubility and stability of the drug. 
The values that are generated in this manner may aid in some 
future investigation into improved solubility and consequently, 
improved formulation of particular anti-cancer drugs. 
( 
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This project will entail the handlingl. of this antitumor agent 
and should be considered a potent substance, requiring proper and 
safe handling in all aspects of the study. 
2. Objectives of this Study: 
The focus of this project is to determine the solubility of AZQ 
in parenterally acceptable solvents. It is expected that a prefor-
mulation study of this compound will provide information to produce 
significant solubility enhancement within these solvent limits. 
Concurrently, it is our intent to ascertain the relative stabi-
lity of AZQ in these solvents and to study the effect of temperature 
on solubility and stability. 
The results of this study should contribute to the generation of 
an essential data base for AZQ, and should also give practical 
guidelines to improve the parenteral administration of this antitumor 
compound. 
1. Recommendations for Handling Cytotoxic Agents 11 , National Study 
Commission on Cytotoxic Exposure, September 1984. Sponsored by 
Bristol Laboratories. 
( 
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3. EXPERIMENTAL 
3.1 Materials 
A. Equipment: 
Waters detectors (UV), Modtls 441 and 4801. 
Waters HPLC Pump, Model 5101. 
HPLC Syringe (250 ml Capacity)l. 
C1a column (µ-Bondapak)l [P/N 273245/NJ 
Cole-Parmer (Linear) Recorder2. 
Mettler H8 Balance3· 
Sartorius Balance 4. 
Rotating Sample Holder with Motor5. 
Millipore Suction Pump and Micro-filters (0.45u)6. 
Wrist-Arm Shaker?. 
Eberbach Shaker8· 
Fisher Magnetic (Thermix) Stirrer9· 
Glassware, i.e. volumetric flasks, Pipettes, Screw cap bottles, 
etc.5· 
Millipore Swiney Adapters6. 
Hypodermic Syringes and NeedleslO. 
Orion Model 811-pH meterll. 
O'Dell Fish tank (25 Gallons) - Used as a water bath12. 
Beckman 1 43 PH - meterl3. 
Hitachi Model - 200 Spectrophotometerl4. 
Perkin - Elmer Chart Recorder (UV-Vis)l5. 
UV-Cuvettes (sizes Sec, lee and 0.5cc)l6. 
18 
Cole-Parmer 1252-00 Circulator (Thermostat)2· 
Texas Instruments (TI55) hand Calculator17. 
1. Waters Products Division, Millipore Corp., Mipford, MA 01757. 
2. Cole-Parmer Instrument Company, C~icago , Illinois, 60648. 
3. Mettler Instrument Corp., Hightstown, N.J. 08520. 
4. Brinkmann (Sartorius) Instruments Westbury, N.Y., 11590. 
5. Department of Pharmaceutics, College of Pharmacy, URI. 
6. Millipore Corp., Bedford, MA 01730. 
7. Burrell Corp., Pittsburg, PA. 
8. Eberbach Corporation, Ann Arbor, Michigan, 48106. 
9. Fisher Scientific Corp . , Fair Lawn, N.J. 07410. 
10. Becton Dickenson and Co, Rutherford, N.J., 07070. 
11. Orion Instruments, Cambridge, MA, 02139. 
12. The Aquarium, N. Main Street, Providence, RI 02906. 
13. Beckman Instruments Inc., Palo Alto, CA 94304. 
14. Hitachi Limited, UV Spectrophotometer, Tokyo, Japan. 
15. Perkin-Elmer Corp., Norwalk, CT, 06856. 
16. Markson Science, Phoenix, Az, 85076. 
17. Texas Instruments, Model TI55 Calculator 
19 
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B. Facilities: 
URI Library, 
URI Computers, 
Department of Pharmaceutics' Laboratory Workspace. 
C. Chemicals 
OMA, lot AM68618 
AZQ (NSC-182906), lot AJ-58-sl9 
Acetonitrile, Lot #521020 
Methanol, Lot 534720 and lot 8644449. 
Sodium Phosphate (Dibasic), lot 7723749. 
Potassium Phosphate (M0nobasic), lot 7229549. 
Propylene glycol , lot 94F-020921. 
Ethyl alcohol 95%, lot CTN 86F0822. 
Distilled Water5· 
Peanut Oil (Arachis Oil) USP, lot C61863523. 
18. Burdick and Jackson, Muskegon, Michigan, 49442. 
20 
19. Developmental Therapeutics Program, National Cancer Institute, 
National Institutes of Health, Bethesda, MD. 
20. E-M Science, Cherry Hill, NJ 08034. 
21. Sigma Chemical Company, St. Louis, Mo., 63178. 
22. U.S. Industrial Chemicals Co., Tuscola , 111. nl953. 
23. Amend Drug and Chemical Co. Inc., East 24th Street, N.Y., NY. 
( 
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3.2 Methods: 
An initial objective of this study was to develop a simple, 
reproducible and sensitive miniaturized HPLC assay for AZQ. The 
method method.of Poochikian and Cradock (32) was used as the basis 
for assay development. 
3.3 Assay Conditions: 
The mobile phase used initially was acetonitrile (CH3CN), 20% 
(V/V), in phosphate buffer (pH of approximately 6.5). A modular 
HPLC, equipped with a constant-flow pump was used. This chroma-
• 
tograph delivered eluent at the rate of 1 ml. per minute to a C1a 
column. Column temperature was ambient. Injections were made with 
a rotary valve injector, equipped with either a 20 or 50 micro-liter 
injection loop. A single-wavelength or a variable-wavelength detec-
tor, set at 254 nm and 0.05 AUFS deflection, was used to detect 
eluted material. A strip-chart recorder was used to record output 
signals. The chart speed was 30 cm per hour. Column-pressure was 
1.0-1.5 psi (x 1,000). 
Chromatographic separations were effected isocratically at room-
temperature. A standard curve was generated by dissolving 25 mg. AZQ 
in 500 ml. phosphate buffer, thereafter making dilutions of this 
solution, with buffer, to yield concentrations of 50, 40, 30, 25, 20 
and 10 micro-grams per ml. 
( 
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3.4 Miniaturization of HPLC Assay for AZQ: 
Due to the small amount of AZQ provided for this study by the 
NCI, a semi -micro-assay method was imperative. Work done by Pooc hikian 
and Cradock (1), indicated that a useful range of concentration for 
the HPLC analysis of AZQ was 5-50 micro-grams per ml. 
Initially, 80 mg. of AZQ was dissolved in 100 ml. of solvent, 
after dilution, the concentration was 40 micro-grams per ml. and the 
sensitivity of the assay was determined. The test sample was then 
reduced to the equivalent of 1 mg. of AZQ in 1 ml. of solvent. 
Appropriate dilution produced a concentration of 32 micro-grams per 
• 
ml., and this concentration proved to be reproducible. This 3 ml. 
sample was then used as the working amount for the solubility study. 
3.5 Validation of HPLC Assay: 
The assay method developed for AZQ was validated for precision, 
sensitivity and reproducibility using Food and Drug Administration 
(FDA) guidelines for the validation of analytical data (33). The 
following data is required for the validation of the assay method: 
A. Data demonstrating that fresh or degraded placebos do not sig-
nificantly interfere with the assay. For drugs that decompose 
during the assay procedure, the method should be stability in-
dicating. 
B. Data should demonstrate sufficient precision, linearity and 
accuracy over the useful range, (approximately 90 to 110% of the 
label claim). 
( 
C. To demonstrate reproducbility or 11 ruggedness 11 , data should be 
presented which shows day-to-day, lab-to-lab, technician-to-
technician, and/or column-to-column variability. 
D. Data should be provided which demonstrates the recovery from 
the actual sample matrix where the nature of the products so 
indicates, e.g. time-release or polymer matrices. 
E. Where necessary, data which demonstrates the specificity of 
the method, and the limits of sensitivity for degradation 
prod ucts or i mpurities, should be provided. 
3.6 Stability: 
23 
The solubility of AZQ in different media was determined by the 
following method: 
Each weighed sample, in excess of literature values, was placed 
in a teflon-lined, screw-cap glass vial (20cc) and the appropriate 
amount of solvent was added. The vials were then capped and sealed 
with Parafilml·, and rotated at approximately 28 R.P.M. in a 
constant-temperature water bath (! 0.1°C), at the temperature of 
25°C for a period of 4 hours to reach equilibrium. 
After the incubation period, the vials were removed for HPLC 
assay. A portion of the sample was then filtered through a 
Millipore filter (0.45 micro-meter) by means of a hypodermic syringe 
(attached to a swiney adapter) and a needle, into a 10 ml. volumetric 
1. American Can Company, Greenwich, CT 06830 
( 
( 
( 
flask, and made up to volume with phosphate buffer diluent (pH 
approx. 6.5). 
The drug concentration was then determined by HPLC. 
For the solubility of AZQ in peanut oil, an extraction method 
24 
was developed. Methanol (100%) was found to be a suitable immiscible 
solvent for extracting AZQ from the Peanut Oil solutions. Tne 
saturated oil samples were shaken against methanol in three volumes 
to effect complete removal of the drug from the oil. The resulting 
methanol solutions were pooled and drug content was determined as 
previously described. 
The pH of the solutions was determined at the time of the assay. 
For each solvent system studied, the stability of AZQ was ascer-
tained by monitoring the appearance of adegradation peak as a 
function of time in these solutions. 
Samples of the drug at a concentration of 30-40 micro-gram per 
ml. were rotated in a water-bath for varying lengths of time, and 
the concentration of active component was determined by HPLC. 
3.7 Effect of Temperature: 
The degree to which elevated temperatures could improve the 
solubility was determined by completing a solubility study of AZQ in 
distilled water, buffer and peanut oil at 25, 30 and 40°c. 
The data was used to estimate the relative energy of activation 
(Ea) for the compound. 
( 
( 
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4. RESULTS AND DISCUSSION 
4.1 Development of the Assay: 
AZQ has a structure amenable to UV detection. Unfortunately, 
the stability of the compound in aqueous solution is poor, and the 
decomposition products interfere with UV analysis. An HPLC method 
has been described in the literature (1,2,14,15,28). 
In order to optimize separation of active compound from degrada-
tion peaks, a number of solvents and solvent mixtures were evaluated 
for suitability as a mobile phase (Table II). As seen in this table, 
a mobile phase of 20:80 Acetonitrile (CH3CN): phosphate buffer pro-
duced the greatest sensitivity and reproducibility. After the assay 
conditions were established, the assay was validated as stability-
indicating by injection of degraded AZQ to freshly prepared solu-
tion. No change in peak height was observed in the main peak. 
Injections of degraded samples showed complete loss of the main peak 
with rapid loss of degradation peaks (Figures 4,5,6) in the aged 
samples. 
TABLE II: EFFECT OF MOBILE PHASE ON THE DETECTION OF AZQ 
Mobi1e Phase Peak Retention 
Mobile Phase Apparent pH He i_g_h t (cm) Time (min.) 
50:50 Methanol: 7.25 1.5 cm 3 minutes 
l~ater(dist.) 
10:90 acetonitrile 6.99 6.1 cm. 14 minutes 
(CH3CN): Phosphate 
buffer (P04 buffer) 
15:85 II II 6.99 12.3 cm. 9.4 minutes 
20:80 II II 7.00 18.7 cm. 6.0 minutes 
( 
a) Calculation of Retention Time: 
Chart Speed = 30 cm/hr. 
= 30 cm/60 min. 
= 5 mm/min. 
Retention time = distance from injection - time (0 mm) to peak 
maximum (in mm). 
~chart speed (5 mm/min.) 
Example: from Figure 9, page 37. 
Distance to peak = 3 cm(= 30 mm). 
Retention time= 30 mm~ 5 mm/min.= 6 minutes. 
FIGURE 4: CHROMATOGRAM OF 1 FRESH 1 AZQ SOLUTION 
Solvent = phosphate buffer (pH = 6.5) 
M.P. = 20% Crl3CN in buffer. 
AUF = 0.05; Lambamax = 254 nm; Loop= 50 micro liter; 
Pressure= 1.5 (xlOOQ) psi; Flow-rate= l ml./min; 
Chart Speed = 30 cm/hour; Retention time = 6 min. 
AZQ 
\ 
., 
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( FIGURE 5: A 50:50 MIXTURE OF FRESH AND DEGRADED AZQ SOLUTIONS 
AUF = 0.05; 
Flo"'' = 1 ml./min . 
Pre"Ssure = 1.5 - 2.0 (x 1,000) psi; 
Larnb amax = 254 nm. 
AZQ solution concentration = 40 micro-
grams per liter for both 'fresh' and 
degraded solutions. 
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FIGURE 6: MOBILE PHASE IS 50:50 METHANOL: DISTILLED WATER 
AUF = 0.01 
Chart-Speed = 30 cm./hr. 
Flow-rate = 1.0 ml./min. 
Pressure = 2.5 (x 1,000) psi 
Loop volume= 50 micro-liter 
28 
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FIGURE 7: MOBILE PHASE IS 10% CH3CN IN PHOSPHATE BUFFER 
AUF = CJ.IO 
Flow rate = 1.0 ml/min. 
Pressure = 2.Spsi (xlOOO) 
Loop vol. = 50 micro liter 
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FIGURE 8: MOBILE PHASE IS 15% CH3CN IN BUFFER 
AUF = 0.10 
Flow rate = 1.0 ml/min. 
Lambdamax = 254 nm 
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FIGURE 9: MOBILE PHASE IS 20% CH3CN IN BUFFER 
AUF = 0.10 
Flow rate = 1 ml/min. 
loop= 50 micro liter 
Lambdamax = 254 nm 
Chart speed = 30 cm./hr. 
I •. 
t 
I 
I' 
. I 
-:--- -
- - -r-- ·-
. i 
. . -· . 
. I 
AZ.Q 
- -- - '· . -
. - I i .. . . I 
. j 
, ___ ___). 
I 
' 
- : 
. ----1 
l 
_____, ·L 
31 
( 
32 
b) The Standard Curve: 
Distilled Water as the solvent for the standard curve was 
ruled out early in this study because of the very rapid hydrolysis 
it causes in AZQ (34) and the low aqueous solubility of the drug, 
(Table I). Phosphate buffer (pH = 6.5) was subsequently used in all 
dilutions of AZQ stock solutions because it provided sufficient sta-
bility of AZQ in solution. 
The standard solution was prepared by dissolving approximately 
25 mg. of AZQ in 500 ml. of buffer (pH= 6.5). The solution was 
stirred with a magnetic stirrer and the resulting solution was then 
filtered through a micro-pore filter (0.45 microns), and degassed. 
The solution was diluted serially with buffer solution, from 50 
to 10 micro-grams per ml. (Table III). The standards were assayed 
and peak heights were measured and used to determine the con-
centrations of the unknown solutions of AZQ. In retrospect, peak 
area would have been more accurate. Since this is only a prelimi-
nary study, peak height was easier to determine as automated equip-
ment was not available. 
From the data, linearity was good (r > 0.99, df = 5) and the 
assay method was sensitive to the extend of 5 mg./ml. (Table III). 
TABLE III: TYPICAL STANDARD CURVE DATA FOR AZQ 
Concentration 
Slope = 0.312 
X-intercept = -0.1 
10 
20 
25 
30 
40 
50 
(JJg. /ml) 
Correlation Coefficient = 0.997 
Peak Height (cm) 
2.90 
5.90 
7.85 
9.55 
12.70 
15.15 
33 
( 
( 
34 
4.2 Miniaturization of the Method: 
In order to have confidence in the values generated with small 
samples, the assay was miniaturized, using progressively smaller 
volumes of AZQ solutions. For the final set of samples, amounts of 
AZQ equivalent to 80 mg. in 100 ml. were prepared in water and 
phosphate buffer. one ml. volumes were taken and diluted to 25 ml., 
the drug content of the solutions was determined against a standard 
curve and results agreed well with previous determinations. Test 
sample volume was then reduced to 3 ml. Aliquots of 0.5 ml. were 
withdrawn and diluted to 10 ml. The concentration of AZQ was deter-
• 
mined and it compared well with initial data. In addition, the 
reproducibility at this level was good. Having decided that a 3 
ml. working volume was satisfactory, it was necessary to validate 
the assay at this micro level. 
4.3 Validation of Assay Method: 
According to the Food and Drug Administration (FDA): Guidelines 
for Submission of Supportive Analytical Data for Methods Validation 
in NDA's (New Drug Applications), (33), the following steps are 
necessary to validate the newly developed HPLC assay for AZQ, repro-
ducibility, linearity and accuracy. Slopes of 4 (four) HPLC runs, 
done on different days, were used to show the variability of the 
assay method. From the data below, it is very clear that the assay 
method is reproducible, as required by the FDA (33). 
( 
Example 1: Reproducibility 
Day # Slope Date of Run 
1 0.3120 5-6-87 
2 0.3273 6-2-87 
3 0.3325 6-4-87 
4 0.3386 6-9-87 
Examp le 2: Linearity 
Day # Correlation Coefficient (r) Date of Run 
1 
2 
3 
4 
df = 5 
0.9970 
0.9998 
0.9997 
0.9997 
5-6-87 
6-2-87 
6-4-87 
6-9-87 
35 
In all the determinations made, the method always exhibited good 
linear responses. 
( 
Example 3: Accuracy 
Run # Date 
-
1 5/6/87 
2 6/2/87 
3 6/4/87 
4 6/9/87 
TOTALS 
-
Theoretical Peak-Height (cm) 
of 10 micro-grams/ml. 
3.03 
3.28 
3.30 
3.30 
12.91 
i) Average= 12.91 cm.~ 4 = 3.2275 cm. 
ii) Average of Measured Peak-heights= 12.85 cm~ 4 
= 3.2121 cm. 
Degree of error= i. ii. 
= (3.2275 - 3.2125) cm. 
% error 
= 0.0150 cm. 
= 0.015 
3.2275 
= 0.45% 
x 100 
36 
Actual Peak-(cm) 
Height Measured 
2.90 
3.25 
3.35 
3.35 
12.85 
• 
The value obtained above, approximately 0.5%, falls well within 
the confidence level of 100 + 10% required by the FDA. 
See next page for Typical Chromatograms of AZQ solutions, Figure 
10. 
( 
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FIGURE 10: TYPICAL CHROMATOGRAMS OF AZQ SOLUTIONS 
Solvent= Phosphate buffer (pH= 6.5). 
Mobi le Phase= 20% CH3CN in phosphate buffer. 
Loop= 50 micro-liters; Flow-rate= 1 ml./min.; 
Pressure= 1.5 x 1,000 psi; AUF = 0.05; Lambdamax = 254nm; 
Chart Speed= 30 cm./hr.; Retention Time= 6 minutes 
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Concentration of AZQ solution = 40 micro-grams/ml. 
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4.4 The Stability of AZQ Solutions: 
Aqueous solutions of AZQ (at a concentration of 50 micro-grams/ 
ml.) degraded approximately 58% in a 12 hour period. During this 
time period, the pH changed from 4.15 to 5.0 (Figure 11), and the 
chromatogram showed evidence of decomposition of the main peak. A 
similar effect was seen in a sample aged 60 (sixty) days, in a dark 
room, at 25°c. 
FIGURE 11: 1 FRESH 1 AND 12 HOURS-OLD SOLUTIONS 
Mobile Phase= 20% CH3CN in buffer; 
Solvent = Distilled Water; 
AUF = 0.05; Lambdamax = 254 nm; Loop = 20 microliters; 
Flow= 1.0 ml./min.; 
Pressure= 1.2 x 1,000 psi.; 
Column = C18; 
Concentration = 50 micro-grams/ml. 
( 
FIGURE 11: 'FRESH' AND 12 HOURS-OLD SOLUTIONS 
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FIGURE 12: DEGRADATION PEAKS OF AZQ SOLUTION, SHOWING TOTAL LOSS OF 
AZQ PEAKS AFTER 60-DAYS 
Solvent= Di stilled Water; 
Flow= 1 ml./min.; 
AUF = 0.1; 
Pressure= 2 x 1,000 psi.; 
Lambd amax = 254 nm; 
Concentration of AZQ solution = 
40 mi crograms/ml. 
41 
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When other solvents were investigated, the results were consider-
ably different. Compared to water, these solutions showed very 
little apparent degradation in the same time period, (See Table IV, 
Figure 11, Figure 15). 
TABLE IV: STABILITY OF AZQ IN DIFFERENT SOLVENTS 
Time Apparent Retention Peak-Height Peak/Height 
Solvent (HR) _Q_H Time(min.) (cm) Ratio 
95% Ethanol 0 9.87 6.2 8.15 4.29 
12 8.63 6.2 8.10 4.05 
Phosphate 0 6.58 6.0 15.40 39.50 
buff er 12 6.58 6.0 15.80 39.50 
Propylene 0 5.82 6.3 5.40 2.70 
glycol 12 5.22 6.3 5.30 2.65 
OMA, 100% 0 12.04 5.6 12.20 2.30 
12 11. 21 5.6 12.20 2.30 
OMA in 0 8.09 5.8 10.20 1. 90 
buff er, 50% 12 7.43 5.8 10.00 1.85 
Peanut Oil 0 6.0 1. 00 1.45 
12 6.0 0.65 0.93 
Distilled 0 4.48 5.8 15.20 30.40 
Water 12 5.80 5.8 6.40 5.30 
It can be noted that the phosphate buffer provides a useful 
aqueous diluent for the solubility study. Therefore, when aliquots 
of AZQ were taken from sample vials, they were diluted to volume 
( 
with phosphate buffer. This insured stability of the drug during 
the assay period (Figure 13 demonstrates the stability of AZQ in 
phosphate buffer solutions). 
OMA was the only system which showed appreciable change in 
retention. This was expected since the literature indicates that 
42 
the UV cut-off point for this solvent is 267 nrn. In the chromatogram 
of this compound, (Figure 14), the main peak of AZQ is much lower 
than degradation peaks in unsaturated solutions. An injection of 
aged sample s in this solvent showed no interference of the main peak 
due to decomposition products. Saturated solutions of AZQ in OMA 
• 
show familiar peaks and retention, after proper dilution. 
( 
( 
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FIGURE 13: THE EFFECT OF AGEING (TIME) ON AZQ SOLUTIONS: 
M.P. = 20~ CH3C~ in Buffer ; Flow= 1.0 ml/min.; Loop= 20 micro liter 
Pressure = 1.5 psi (x1000); Lambdamax = 254nm; Chart speed = 30cm/hr 
Solvent = Buffer (pH = 6.5); AZQ cone. = 50 micro gram/ml; 
Retention time = 6 min. 
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FIGURE 14: CHROMATOGRAM OF AZQ IN OMA 
Solvent = OMA, 100%; 
Mobile Phase= 20% CH3CN in buffer; 
Loop= 20 micro-liters; Flow= l ml./min; Pressure= 1.5 x 1,000 psi; 
AUF = 0.05; Lambdamax = 254 nm; 
Chart Speed= 30 cm/hr.; Retention Time= 6 minutes 
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FIGURE 15: EFFECT OF TIME ON pH, PEAK-HEIGHT AND RETENTION-TIME OF 
AZQ IN DIFFERENT SOLVENTS 
Zero Time After 12 hours 
15(a) 95% Ethanol 
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In all determinations, HPLC conditions were similar, ie. 
Auf = 0.05; 
Lambdamax = 254 nm; 
Loop volume = 50 micro=liters; 
Pressure= 1.0 - 1.5 (xl,000) psi; 
Flow rate= 1 ml./min.; 
Chart-speed = 30 cm/hr. 
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FIGURE 15: EFFECT OF TIME ON pH, PEAK-HEIGHT AND RETENTION-TIME OF 
AZQ IN DIFFERENT SOLVENTS (cont.) 
Zero Time After 12 hours 
15(b) Phosphate Buffer: 
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FIGURE 15: EFFECT OF TIME ON pH, PEAK-HEIGHT AND RETENTION-TIME OF 
AZQ IN DIFFERENT SOLVENTS (cont.) 
Zero Time After 12 ho urs 
lS(d) 50:50 OMA: Phosphate Buffer 
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FIGURE 15: EFFECT OF TIME ON pH, PEAK-HEIGHT AND RETENTION-TIME OF 
AZQ IN DIFFERENT SOLVENTS (cont.) 
Zero Time 
15 (e) 100% OM.'.\: 
. -- _!_ • 
- ·- - - .. 
AZQ 
I . 
·-' · -- . - ' -
' . 
__ J ___ J 
' . 
~-- r. ·--·-
i 
- l .. 
1 I 
T 
.. _..L _ _ 
'. : : I I . i 1 ' . ~- .!. _ _. j_i . ~ L 
l ' . j ~ 
After 12 ho ur s 
• 
r-
1 
- ;-
I 
! 
I 
.. : -
I 
' 
-- --- - - ,-
I 
. .. -
j . 
( 
50 
Depending on the solvent environment, AZQ can be expected to 
undergo degradation by a number of different pathways (35,36). When 
the pH is strongly acidic (pH = 1), AZQ degrades instantaneously to 
yield a dialcohol, whereas under alkaline conditions, AZQ undergoes 
simple stepwise and consecutive hydrolytic cleavage of the aziridine 
rings to produce the monoalcohol, then finally the dialcohol (37). 
Buffer systems have also been shown to have a mixed effect on the 
degradation (38). At acid pH and above pH 8, degradation increases 
significantly. Increasing the buffer concentration will generally 
also increase the rate of disappearance of AZQ from solution 
although examination of the chromatograms of degraded solutions has 
shown that this reaction is partially a function of phosphate ion. 
For our work, a phosphate buffer (pH 6.5) showed good stability over 
a 12-hour period (Figure 15(b) and Table V), and this has been shown 
to be the pH of optimal stability (39). 
In this study, stability was monitored by measuring pH and peak-
height ratio of the main peak to a major degradation peak as a func-
tion of time. The results are summarized in Table V for solutions 
at an initial concentration below saturation (40 ugm/ml). As can be 
seen, the compound was very unstable in water and decomposed 58% 
after 12-hours. This is in agreement with NCI data which showed 67% 
loss. Additionally, an aqueous sample stored at 25°C in the dark, 
showed very little AZQ concentration after 60 days (Figure 12). 
This was not unexpected after observing the 12-hour data. 
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TABLE V: STABILITY OF UNSATURATED AZQ SOLUTIONS 
Solvent 
Distilled Water 
Phosphate 100% Buff e~ 
(pH = 6.5) 
OMA in Buffer, 5:95 
OMA in Buffer, 10:90 
OMA in Buffer, 25:75 
OMA in Buffer, 50:50 
OMA, 100% 
Ethanol, 95% 
Peanut Oil 
Propylene Glycol 
Time App. Ret. Pk.Ht Pk.Ht. Pk.Ht. AZQ. % 
(hr.) pH (Min.) (cm) degr.(cm) Ratio mg/ml Change 
0 4.48 5.8 15.20 30.40 0. 50 9.80 
12 5.80 5.8 6.40 5.30 1. 21 4.16 57.5% 
0 6.58 6.0 15.80 0.40 39.50 10.18 
12 6.58 6.0 15.40 0.40 38.50 9.93 2.5% 
0 6.03 6.0 5.80 5.52 1.05 3.45 
12 6.83 6.0 5.60 5.44 1.03 3.33 3.4% 
0 6.43 6.0 4.90 5.10 0.96 2.91 
12 6.87 6.0 4.40 5.43 0.81 2.62 10.1% 
0 6.88 6.0 5.40 7.83 0.69 3.21 
12 7.10 6.0 5.30 7.79 0.63 3.15 1. 9% 
0 8.09 5.8 10.20 5.37 1. 90 6.04 
12 7.43 5.8 10.00 5.41 1.81 5.93 1. 95% 
0 12.0 5.6 12.00 5.22 2.30 7 .11 
12 11. 21 5.6 12.00 5.22 2.30 7 .11 0.0% 
0 9.87 6.2 8.50 1. 98 4.29 5.23 
12 8.63 6.2 8.10 2.00 4.05 4.99 4.70% 
0 - 6.0 1.00 0.69 1.45 2.28 
12 
- 6.0 0.65 0.70 0.93 1. 98 13 .10% 
0 5.82 6.3 5.40 2.00 2.70 3.19 
12 5.22 6.3 5.30 2.00 2.65 3.13 1.90% 
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~CI data has also shown that aqueous solutions of this drug 
decompo se readily at room-temperature in 5% OMA, losing 18% of 
active-ingredien t in 8 hours (27, 28) . In our investigation, a 
series of OMA solutions in pH 6.5 buffer was prepared to evaluate 
this effect. In fact, the same effect was noticed at 5% OMA, where 
a 1% increase in drug loss was observed. At 10% OMA , the degree of 
degradation had increased to 10%. Further increase in OMA con-
centration, reversed this effect such that at 100% OMA there was 
littl e chanye in t he in iti al co n ce ~ t r atio n . It is unclea r at t his 
ti me what th e actual mechanism is for this behavior. However, it 
• 
would be reasonable to assume that addition of OMA would alter the 
solubility of buffer ingredients, thus producing a shift in degrada-
t ion rate as described previously (Figure 16). 
Alcohol has also been suggested as a co-solvent for this compound. 
Solutions of AZQ in this vehicle showed a drop in pH of approxima-
tely 1 unit over the test period and an estimated loss of drug of 
5%. this solvent would therefore appear to be useful as a solubi-
lity enhancer since the degree of change is relatively small, and 
alcohol is acceptable for intravenous use. 
Propylene glycol should provide some improvement in solubility 
since it is often used as a co-solvent for semi-polar compounds. 
Unsaturated solutions of AZQ in propylene glycol showed little 
change in pH or drug content over 12-hours. Therefore, it could be 
considered as a solvent for this drug. 
Peanut Oil was also evaluated for improving the solubility and 
stability of AZQ. Unsaturated solutions using this solvent required 
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extraction by methanol before analysis by HPLC. Amounts of active 
dr ug in sol ution were small and the re for e any results can be con-
sidered inconclusive. 
In summary, the stability study indicated that AZQ was stable in 
three solvents (OMA, Ethanol 95% and Propylene glycol) for at least 
12 ho urs . This degree of st abili t y co uld potentia l ly prov ide t he 
opportunity to develop a reconstitutable product. Justification for 
this type of product would also depend on the degree of solubility 
enh ancement whi ch could be ac hieved with t hese solvents . Fol lowing 
are the results of a solubi lity study of AZQ. 
• 
4.5 Solubility of AZQ: 
In order to study the solubilizing capacity of the various 
solvents, excess drug was exposed to solvents in vials as described 
previously. In one trial, samples were filtered and assayed after 
24-hours, while another trial was completed at a 4 hour sampling 
time. This allowed evaluation of the stability of concentrated 
so l ut ions as we ll as confirmat ion of solu bility and t ime r eq ui red 
for equilibrium. A previous study showed that 12 hours was more 
than sufficient for equilibrium. Since decomposition is occurring 
simultaneously, it was interesting to monitor development of degra-
dation. Degradation peaks were evident in samples showing loss of 
AZQ at 24 hours. 
Table VI summarizes the results of these investigations. In 
comparing results at 4 hours and 24 hours, a slight decrease in con-
centration (0.76 and 7.6%) can be seen in OMA and ethanol systems, 
respectively, when 24 hours was used for equilibrium. This was not 
( 
( 
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considered to be extensive. There was a slight increase in solubi-
lity over the same time period in the aqueous and buffered systems 
(33.3i and 25.9%). Four hours therefore appeared to be sufficient 
time to reach equilibrium. In the case of propylene glycol and 
peanut oil, four hour samples were not prepared because of the 
limited amount of AZQ available, and since the 24-hour samples gave 
a good indication of solubility. 
The saturation solubility of AZQ in water was found to be 
approximately 0. 49 mg./ml. (n=3 ) . This is in the range of results 
reported by NCI, (Table 1). Pl iosphate buffer produced results simi-
lar to but slightly lower than water (0.35 mg./ml.). This should 
not be unreasonable if one considers competition for solubility with 
buffer ingredients. A distinct advantage of phosphate buffer was 
improved stability, particularly at sub-saturated levels of the drug. 
In the case of ethanol, there was a ten-fold increase in solubi-
lity (3.7 mg./ml.) , and as discussed previously, the rate of decom-
position in ethanol solutions was low. Thus ethanol appears to be 
useful in providing improved solubility of AZQ. As mentioned 
before, ethanol is approved for intravenous (IV) use and it would 
therefore appear to be a suitable solubilizer of this drug. 
The effect of propylene glycol was disappointing. The solubility 
in this solvent was approximately the same as in water (0.46 mg./ml). 
This solvent is very viscous and made analysis difficult at the 
filtering step. Perhaps a repeat of this portion of the test would 
have shown slightly higher results as had been anticipated since it 
is often used to improve solubility. Peanut Oil showed similar 
( 
( 
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effects. AZQ was not easily wetted by the viscous oil and did not 
appear to be very soluble in this material (0.05 mg./ml). Extraction 
Extraction with methanol created an additional opportunity for the 
loss of product. The disappointingly short peak heights are really 
too small to draw any significant conclusions. Both these results 
would indicate that neithe r of these t wo solvents would be accep-
table in an injectable dosage system. However it must be recognized 
that lack of samples prevented more extensive evaluation of these 
solvents. 
OMA was by far the most effective solvent for AZQ. A saturation 
concentration of 44 mg./ml. was achieved with this solvent. These 
results are approximately double those reported by the NCI but the 
NCI data is a useful comparison. It should be noted that the NCI 
data are a rough estimate of solubility. While the DMA results are 
encouraging, the ratio of OMA required to achieve this level of 
solubility exceeds permissible concentrations for human use. OMA is 
an animal teratogen (40), and it is recommended that OMA concentra-
tions not exceed 5%. Given the structural similarity of alkyl amides, 
one could expect the same trend in these solvents (40). 
In summary, OMA can achieve a significant increase in solubility 
of AZQ. However, clinical application would be limited. 
57 
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TABLE VI: SOLUBILITY OF AZQ AT 25°C 
Incubation Peak Milligrams 
Solvent Time (hrs) Height (cm) per ml. % Change 
Distilled 4 7.35 0.42 
Water 24 9.95 0.56 +33. 28 
95% Ethanol 4 7.00 3.89 
24 6.63 3.59 -7.64 
Propylene 4 
Glycol 24 8.48 0.46 
OMA 4 8.15 44.38 
24 7.60 44.04 -0. 77 
Peanut (Ji l 4 
24 Ll.95 0.055 
( Phosphate 4 6.00 0.296 Buff er 24 7.40 0.400 +25.98 
(pH 6.5) 
( 
( 
4.6 Effect of Temperature on AZQ Solubility: 
Standard Curve: 
Flask # Cone. AZQ (ug/ml. 
1 50 
2 40 
3 30 
4 25 
Calculations from Standard Plot: 
Slope = 0.356 
X-intercept = -1.1525 
Correlations Coefficient = 0.999 
Mean Value= 11.75 
Results: 
58 
Average 
Peak-He i_ght (cm) 
16.7 
13.0 
9.5 
7.8 
TABLE VII: THE EFFECT OF TEMPERATURE INCREASE ON SOLUBILITY 
Temp. Time pH Average 
°C (hours) Change Pk. Ht. 
(cm) 
30 0 6.76 3.6 
4 6.52 2.5 
35 0 6.76 3.6 
4 6.52 5.0 
40 0 6.76 3.6 
4 6.51 3.8 
ug/ml. 
from Dilution 
Plot Factor 
13. 35 
10.26 20 
13. 35 
17.28 20 
13. 35 
13. 91 20 
AZQ % 
mg/ml Change 
0.267 
0.206 -23.22 
0.267 
0.346 +29.59 
0.267 
0.278 + 4.12 
( 
( 
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The effects of temperature on the solubility of AZQ were studied 
at 25,30,35 and 40°c. Solubility of AZQ at 25°C was studied and 
reported in a previous chapter. A previous study by Poochikian and 
Cradock (41) had shown the temperature dependence of the disappear-
ance of AZQ from solution. In that study, the apparent Arrhenius 
parameters were calculated from the regression equation (r > 0.99 ) 
and were found to be as follows: the apparent activation energy (Ea) 
was 14.0 Kcal per mole, and the frequency factor (A) was 7.70 x io3 
sec -1 
From the solubility versus temperature plot (Figure 17), it is 
• 
apparent that raising the water-bath temperature from 25°C to 30°C 
and 35°C respectively, improved slightly the amount of AZQ dissolved 
in the buffer solution and incubation temperature of 35°C provided 
maximum solubility of the drug. This is not unexpected since evi-
dence gathered by Poochikian and Cradock (41) showed that more 
degradation of AZQ occured at higher temperatures. Elevating the 
temperature to 40°C increased the loss of AZQ. 
An apparent activation energy of 38.0 Kcal/mole and a frequency 
factor of 8.3 x 103 sec.-1 can be estimated because of the limited 
amount of material available, this portion of the study could not be 
replicated more than twice and the results should only serve as a 
rough estimate of these parameters. 
In summary, this study has generated data that can help to iden-
tify the solubility characteristics of AZQ. There were a number of 
frustrating problems arising from the work which limit the applica-
tion of the results. Namely, the compound is unstable in an aqueous 
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medium, solubility is relatively poor, and availability of the drug 
restricted the extent of experimentation. Developing a reliable 
method for identifying AZQ in small quantities was a major achieve-
ment. The results obtained with the micro-method agreed well with 
other data. Enhanced solubility and stability of this compound in 
solvents such as ethanol and OMA is noteworthy. However, acceptabl e 
use levels of these solvents must be of concern. Ethanol would 
obviously be more appropriate as a parenteral solvent since it is 
1; idely used (socially) in humans and would be expected to have less 
serious side-effects than the OMA 1vhich provided maximal solubility 
enhancement. 
Future work in this area could focus on the use of sugars, albu-
mins, ureas, and other natural substances for solubility improve-
ment. Alternatively, unique delivery systems such as monoclonal 
antibodies, liposomes, etc. might provide sufficient blood levels of 
this drug. 
While the results of this study are not overly profound, the 
work did provide an opportunity to learn solubility techniques, good 
laboratory procedures, and demonstrated the need for considering 
miniaturization studies for drugs undergoing preliminary preformu-
lation and clinical studies. 
( 5. CONCLUSIONS AND SUMMARY 
1. A rapid, simple, sensitive and selective stability-indicating 
high-performance liquid chromatographic (HPLC) micro-assay 
method was developed and validated. 
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2. The solubility of AZQ ~as found to be quite low in water (0.49 
mg/ml.). Phosphate buffer did not improve ~ZQ solubility which 
was even lower (0.35 mg/ml.) in this solvent. However, stabil-
ity was much a distinct advantage in this aqueous system. 
3. OMA and Ethanol improved the sol6bility of AZQ significantly. 
The use of OMA as a solvent is limited by safety considerations 
and it would appear that ethanol may be the most practical 
solvent at this point in time for AZQ. 
4. Propylene glycol could be a useful co-solvent for AZQ but the 
degree of enhancement is not great. 
5. Peanut oil was a disappointingly poor solvent. Increasing the 
time and temperature of agitation did not improve its performance 
as a solvent. 
6. Raising the temperature of incubation during agitation of the 
solutions of AZQ in Phosphate buffer did not significantly 
improve the solubility. Maximal enhancement of solubility seemed 
to peak at 35°C, but raising the temperature of the solution 
only accelerated the rate of degradation as discussed earlier 
in this study. 
( 
( 
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